Historical data shows that a consistent $500 monthly investment into Coherus Oncology, Inc. (CHRS) starting in 2020 would have turned a total investment of $49K into $22K today. This represents a total return of -55.3% over the 6-year period, compounding through dividend reinvestment and market growth.
The Impact of Dividend Reinvestment (DRIP)
Coherus Oncology, Inc. does not currently pay a notable dividend. For growth-focused stocks like CHRS, dollar cost averaging relies entirely on price appreciation. Over the 6-year period, the strategy successfully captured the stock's price movements, resulting in a final portfolio value of $22K without the need for dividend reinvestment.
CHRS vs. S&P 500 (SPY) Benchmark
When comparing this dollar cost averaging strategy against a broad market index,CHRS underperformed the S&P 500 ETF (SPY). The same $500 monthly contributions into SPY would have grown to $87K, compared to CHRS's $22K.